Latest Breaking News On - Hercules capital debt facility - Page 1 : vimarsana.com

enGene Reports First Quarter 2024 Financial Results and Recent Corporate Progress

/PRNewswire/ - enGene Holdings Inc. (Nasdaq: ENGN or "enGene" or the "Company"), a clinical-stage genetic medicines company whose non-viral, intravesical lead.

United statesJason hansonDerivatized oligochitosanLota zothDgene incForbion european acquisition corporationExchange commissionCompany board of directorsCompany annual report on formCompany audit committee chairGene holdings incGene holdingsChief executive officerBusiness highlightsOversubscribed private placementHercules capital debt facility

EnGene Reports First Quarter 2024 Financial Results and Recent Corporate Progress

Pivotal phase 2 LEGEND study of EG-70 in BCG-unresponsive non-muscle invasive bladder cancer remains on track with interim data anticipated in mid-2024 Closed a $200 million oversubscribed private.

United statesLota zothDerivatized oligochitosanJason hansonGene holdings incDgene incCompany audit committee chairForbion european acquisition corporationExchange commissionCompany annual report on formCompany board of directorsGene holdingsChief executive officerBusiness highlightsOversubscribed private placementHercules capital debt facility

enGene Reports Full Year 2023 Financial Results and Recent Operational Progress

enGene Reports Full Year 2023 Financial Results and Recent Operational Progress
lelezard.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from lelezard.com Daily Mail and Mail on Sunday newspapers.

United statesLota zothRichard bryceRyan dawsDerivatized oligochitosanAlex nicholsJason hansonForbion european acquisition corpPublic companyClinical program progressCompany audit committee chairGene holdings incCompany annual report on formExchange commissionCompany board of directorsForbion european acquisition corporation

enGene Reports Full Year 2023 Financial Results and Recent Operational Progress

Achieved primary and secondary endpoints in Phase 1 portion of LEGEND study in non-muscle invasive bladder cancer (NIMBC); pivotal portion underway with.

United statesAlex nicholsRichard bryceRyan dawsLota zothDerivatized oligochitosanJason hansonPublic companyForbion european acquisition corporationClinical program progressCompany board of directorsExchange commissionForbion european acquisition corpCompany audit committee chairGene holdings incCompany annual report on form